Evonik has launched a series of new formulations of L-Ornithine-L-Aspartate (LOLA) at CPhI in Madrid. The new formulations aim to simplify the administration of this therapeutic agent for liver diseases. LOLA supports the reduction of ammonia concentrations in patients with a damaged liver, a problem globally on the rise. The existing delivery forms were injectable or powders, which can be difficult to prepare and unpleasant to drink.      “Our aim was to increase the acceptance of patients by...